Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KROS

Keros Therapeutics Inc

Nov 07 • 04:00PM ET

16.20

+0.03 0.19 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT VRTX ALNY IONS ARWR TVRD BLUE RGNX MCRB PBYI

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO VHT LABU

Scroll to Statements

Index	RUT	P/E	10.50	EPS (ttm)	1.54	Insider Own	6.77%	Shs Outstand	40.63M	Perf Week	6.44%
Market Cap	493.55M	Forward P/E	-	EPS next Y	-3.79	Insider Trans	-83.15%	Shs Float	28.40M	Perf Month	0.50%
Enterprise Value	-182.49M	PEG	1.30	EPS next Q	-0.62	Inst Own	102.61%	Short Float	13.44%	Perf Quarter	21.35%
Income	64.45M	P/S	2.00	EPS this Y	137.29%	Inst Trans	-27.66%	Short Ratio	5.48	Perf Half Y	18.68%
Sales	246.72M	P/B	0.94	EPS next Y	-303.25%	ROA	9.75%	Short Interest	3.82M	Perf YTD	2.34%
Book/sh	17.32	P/C	0.71	EPS next 5Y	8.10%	ROE	10.43%	52W High	72.37 -77.62%	Perf Year	-74.11%
Cash/sh	22.76	P/FCF	5.67	EPS past 3/5Y	-25.74% -48.13%	ROIC	8.97%	52W Low	9.12 77.63%	Perf 3Y	-67.35%
Dividend Est.	-	EV/EBITDA	-4.05	Sales past 3/5Y	-43.89% -18.71%	Gross Margin	99.42%	Volatility	4.30% 4.59%	Perf 5Y	-68.73%
Dividend TTM	-	EV/Sales	-0.74	EPS Y/Y TTM	130.42%	Oper. Margin	17.67%	ATR (14)	0.64	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	29.86	Sales Y/Y TTM	37798.31%	Profit Margin	26.12%	RSI (14)	61.88	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	29.86	EPS Q/Q	87.28%	SMA20	6.79%	Beta	0.89	Target Price	23.62
Payout	-	Debt/Eq	0.02	Sales Q/Q	3575.77%	SMA50	4.53%	Rel Volume	1.90	Prev Close	16.17
Employees	169	LT Debt/Eq	0.02	Earnings	Nov 05 AMC	SMA200	18.96%	Avg Volume	697.17K	Price	16.20
IPO	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	82.82% 200.25%	Trades		Volume	1,327,820	Change	0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$26
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral	$18
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral	$15
Dec-16-24	Reiterated	Oppenheimer	Outperform	$102 → $63
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-24	Reiterated	H.C. Wainwright	Buy	$100 → $47
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-05-25 05:40PM	Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 06:00AM	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares (GlobeNewswire) +9.83%
Oct-15-25 06:30AM	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital (GlobeNewswire)
08:00AM	Loading…
Sep-08-25 08:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting (GlobeNewswire)
Aug-28-25 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-21-25 08:30AM	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment (PR Newswire) +6.61%
06:56AM	Keros gains FDA orphan drug status for DMD treatment KER-065 (Pharmaceutical Technology)
Aug-20-25 09:48AM	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-06-25 05:45PM	Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.29%
04:15PM	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 (GlobeNewswire)
04:01PM	Keros Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 11:40AM	KROS vs. EXAS: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-23-25 10:54AM	Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? (Zacks) +5.10%
11:28AM	Loading…
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
08:00AM	Loading…
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%
06:00AM	Keros Therapeutics Announces Review of Strategic Alternatives (GlobeNewswire)
Mar-31-25 06:00AM	Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (GlobeNewswire) -5.56%
Mar-21-25 09:55AM	Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet (Zacks)
Mar-05-25 09:55AM	Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade (Zacks)
Feb-28-25 05:00PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Feb-26-25 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 08:00AM	Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:53AM	Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-25 08:00AM	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire) +5.06%
Jan-20-25 09:35AM	Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround (Zacks)
Jan-16-25 09:35AM	Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks (Zacks)
Jan-15-25 06:30AM	Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial (GlobeNewswire) -16.51%
Dec-14-24 06:50AM	Keros Therapeutics price target raised to $28 from $11 at Wells Fargo (TipRanks)
Dec-12-24 04:11PM	Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug (Investor's Business Daily) -73.15%
09:15AM	Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study (Investor's Business Daily)
06:02AM	Keros shares collapse on unanticipated setback for lung disease drug (BioPharma Dive)
06:00AM	Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial (GlobeNewswire)
Dec-09-24 07:30PM	Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-04-24 04:31AM	Takeda licensed for anaemia therapy by Keros Therapeutics (Pharmaceutical Technology) +8.85%
Dec-03-24 12:37PM	Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst (Benzinga) +9.78%
07:00AM	Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics (Business Wire)
07:00AM	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
Nov-26-24 08:00AM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Nov-06-24 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire) +6.18%
08:00AM	Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Nov-05-24 09:00AM	Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-16-24 08:00AM	Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer (GlobeNewswire)
Sep-12-24 08:00AM	Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-24 03:24PM	Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Sep-03-24 08:00AM	Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial (GlobeNewswire) +5.38%
Aug-28-24 08:00AM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-07-24 11:53PM	KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -6.89%
04:01PM	Keros Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-17-24 04:01PM	Keros Therapeutics Announces Leadership Updates (GlobeNewswire) -9.68%
06:00AM	Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association (GlobeNewswire)
Jun-04-24 08:00AM	Keros Therapeutics to Host a Corporate Update Conference Call and Webcast (GlobeNewswire)
Jun-03-24 08:00AM	Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 04:01PM	Keros Therapeutics Appoints Jean-Jacques Bienaime to its Board of Directors (GlobeNewswire)
04:01PM	Keros Therapeutics Appoints Jean-Jacques Bienaim to its Board of Directors (GlobeNewswire)
May-14-24 10:00AM	Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association (GlobeNewswire)
May-10-24 01:25PM	Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials (GuruFocus.com) -5.78%
May-08-24 12:54PM	KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
Mar-14-24 08:00AM	Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
Mar-05-24 08:00AM	Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference (GlobeNewswire)
Feb-28-24 04:42PM	Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 (GuruFocus.com)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
08:50AM	Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-21-24 09:55AM	Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect? (Zacks)
Feb-12-24 08:50AM	Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why (Zacks) +7.02%
Jan-31-24 09:55AM	Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know (Zacks)
Jan-29-24 08:00AM	Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-24-24 08:50AM	Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-23-24 09:55AM	Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-15-24 09:55AM	How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46% (Zacks)

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pontifax Management 4 G.P. (20	10% Owner	Oct 15 '25	Sale	17.75	4,787,331	84,975,125	0	Oct 17 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '25	Sale	17.75	5,389,264	95,659,436	0	Oct 15 01:24 PM
Rovaldi Christopher	Affiliate	Sep 12 '25	Proposed Sale	15.71	85,306	1,340,157		Sep 12 04:45 PM
ADAR1 Capital Management, LLC	10% Owner	Apr 09 '25	Buy	10.13	934,258	9,464,512	4,392,737	Apr 11 09:57 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	0.30	49,367	14,810	302,223	Apr 07 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KROS

Keros Therapeutics Inc

Upgrade your FINVIZ experience